MARKET DEFINITION

A class of drugs known as calcium channel blockers (CCBs) is frequently prescribed to treat heart and blood vessel conditions like hypertension (high blood pressure), angina, some abnormal heart rhythms, and Raynaud's phenomenon. Some calcium channel blockers can reduce blood pressure by slowing the heart rate. The drugs can also be used to control an irregular heartbeat and lessen angina, or chest pain. The body's muscles also need calcium to function properly. This mineral can enter muscle cells through ion channels, which are minuscule pores on the cell surface. Calcium cannot enter muscle cells through a specific pathway in the heart and blood vessel walls, but calcium channel blockers prevent this from happening. CCBs are also used to treat hypertension because they can lower blood pressure. Additionally, CCBs lower heart rates, which helps them manage some abnormal heart rhythms like atrial fibrillation. Even though the heart can pump blood more easily, it uses less oxygen. By reducing the heart's oxygen demand, CCBs can be used to treat or prevent angina.

MARKET DYNAMICS

The rise of cardiovascular diseases in various forms is one of the main factors fueling the market's expansion. Additionally, the market is growing exponentially due to the rising demand for drugs taken orally. Increased clinical research and government initiatives to support market expansion have also seen a surge in popularity. However, the high costs incurred by such agent limit market expansion. Additionally, the market has a chance to expand due to rising cardiovascular awareness and an increase in the number of distribution channels in developing nations.

REPORT SCOPE

The report titled “Global Calcium Channel Blocker Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Calcium Channel Blocker market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Calcium Channel Blocker market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Calcium Channel Blocker Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION

The Global Calcium Channel Blocker Market is segmented based on Product Category, Material Type, End User, and region. Based on Product Category, the market has been segmented into Facial Implants, Breast Implants, Pectoral and Abdominal Implants, Testicular Implants, Upper and Lower Limb Implant, and Others whereas based on Material Type, the market comprises Metal and Metal Alloys, Cobalt Chromium Alloys, Titanium, Ceramics, Polymers, and Others. Based on End User, the market has been segmented into Hospital, Specialty Clinics, and Others.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Calcium Channel Blocker market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Calcium Channel Blocker market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Calcium Channel Blocker market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Calcium Channel Blocker industry in the past three years.

Key players in the Global Calcium Channel Blocker Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

• 3M
• Allergan Aesthetic (AbbVie, Inc.)
• Danaher
• Dentsply Sirona
• GC Aesthetics
• Institut Straumann AG
• POLYTECH Health & Aesthetics GmbH
• Sientra, Inc.
• Zimmer Bionet
• Cochlear Ltd.
• Johnson & Johnson Services, Inc.
• Envista
• BioHorizons
• Osstem UK
• MEGA’GEN Implant Co.,Ltd.

COVID-19 IMPACT ANALYSIS ON GLOBAL CALCIUM CHANNEL BLOCKER MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

1. What is the current size of the global Calcium Channel Blocker market?
2. What will be the growth rate of the market over the forecast period?
3. Who are the key manufacturers/vendors in the Calcium Channel Blocker market space?
4. What are the major market opportunities and market risks faced by the market?
5. What is the impact of COVID-19 on the market?
6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
7. What are the key outcomes of Porter's five forces model?
8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

• The report offers comprehensive data on the Calcium Channel Blocker market elaborating on the current state and future growth prospects both globally and regionally
• It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
• The report offers deep-dive insights into each market segment and critical factors responsible for its growth
• The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
• The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
• Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
• The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity
 
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Indication
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
 
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Drug Class Trends
3.2.2. Route of Administration Trends
3.2.3. Indication Trends
3.2.4. End User Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Calcium Channel Blocker Market
3.6. COVID-19 Impact Assessment in Calcium Channel Blocker Market
3.6.1. Impact Assessment on Global Calcium Channel Blocker Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape
 
Chapter 4. Global Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
4.1. Global Calcium Channel Blocker Market Share, By Drug Class, 2017 - 2028 (USD Million)
4.1.1. Dihydropyridine
4.1.1.1. Nifedipine
4.1.1.2. Amlodipine
4.1.2. Nondihydropyridines
4.1.2.1. Diltiazem
4.1.2.2. Verapamil
 
Chapter 5. Global Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
5.1. Global Calcium Channel Blocker Market Share, By Route of Administration, 2017 - 2028 (USD Million)
5.1.1. Oral
5.1.2. Parenteral
5.1.3. Others
 
Chapter 6. Global Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
6.1. Global Calcium Channel Blocker Market Share, By Indication, 2017 - 2028 (USD Million)
6.1.1. Hypertension
6.1.2. Coronary Spasm
6.1.3. Angina Pectoris
6.1.4. Supraventricular Dysrhythmias
6.1.5. Hypertrophic Cardiomyopathy
6.1.6. Pulmonary Hypertension
6.1.7. Others
 
Chapter 7. Global Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
7.1. Global Calcium Channel Blocker Market Share, By End User, 2017 - 2028 (USD Million)
7.1.1. Hospital
7.1.2. Homecare Settings
7.1.3. Specialty Clinics
7.1.4. Ambulatory Surgical Centers
7.1.5. Others
 
Chapter 8. Global Calcium Channel Blocker Market Overview, By Geography, 2017 - 2028 (USD Million)
8.1. Global Calcium Channel Blocker Market Share, By Geography, 2017 - 2028 (USD Million)
8.1.1. Market Route of Administration and Projections, by Countries, 2017 - 2028 (USD Million)
8.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)
 
Chapter 9. North America Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. North America Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market Route of Administration and projections, 2017 - 2028 (USD Million)
9.1.2. North America Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.1.3. North America Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
9.1.4. North America Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
9.1.5. North America Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
9.2. North America Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. U.S. Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. U.S. Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.1.2. U.S. Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
9.2.1.3. U.S. Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.1.4. U.S. Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.2. Canada Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. Canada Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.2.2. Canada Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
9.2.2.3. Canada Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.2.4. Canada Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.3. Mexico Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. Mexico Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.3.2. Mexico Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
9.2.3.3. Mexico Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.3.4. Mexico Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
 
Chapter 10. Europe Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. Europe Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market Route of Administration and projections, 2017 - 2028 (USD Million)
10.1.2. Europe Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.1.3. Europe Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
10.1.4. Europe Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
10.1.5. Europe Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
10.2. Europe Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. Germany Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. Germany Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.1.2. Germany Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
10.2.1.3. Germany Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.1.4. Germany Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.2. France Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. France Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.2.2. France Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
10.2.2.3. France Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.2.4. France Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.3. UK Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. UK Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.3.2. UK Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
10.2.3.3. UK Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.3.4. UK Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.4. Italy Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
10.2.4.1. Italy Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.4.2. Italy Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
10.2.4.3. Italy Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.4.4. Italy Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.5. Spain Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
10.2.5.1. Spain Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.5.2. Spain Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
10.2.5.3. Spain Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.5.4. Spain Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.6. NORDIC Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
10.2.6.1. NORDIC Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.6.2. NORDIC Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
10.2.6.3. NORDIC Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.6.4. NORDIC Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.7. Russia and CIS Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
10.2.7.1. Russia and CIS Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.7.2. Russia and CIS Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
10.2.7.3. Russia and CIS Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.7.4. Russia and CIS Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.8. Rest of Europe Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
10.2.8.1. Rest of Europe Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.8.2. Rest of Europe Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
10.2.8.3. Rest of Europe Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.8.4. Rest of Europe Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
 
Chapter 11. Asia Pacific Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. Asia Pacific Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market Route of Administration and projections, 2017 - 2028 (USD Million)
11.1.2. Asia Pacific Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.1.3. Asia Pacific Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
11.1.4. Asia Pacific Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
11.1.5. Asia Pacific Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
11.2. Asia Pacific Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. India Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. India Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.1.2. India Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
11.2.1.3. India Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.1.4. India Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.2. China Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. China Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.2.2. China Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
11.2.2.3. China Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.2.4. China Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.3. Japan Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Japan Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.3.2. Japan Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
11.2.3.3. Japan Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.3.4. Japan Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.4. ASEAN Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
11.2.4.1. ASEAN Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.4.2. ASEAN Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
11.2.4.3. ASEAN Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.4.4. ASEAN Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.5. South Korea Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
11.2.5.1. South Korea Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.5.2. South Korea Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
11.2.5.3. South Korea Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.5.4. South Korea Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.6. Australia Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
11.2.6.1. Australia Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.6.2. Australia Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
11.2.6.3. Australia Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.6.4. Australia Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.7. Rest of Asia Pacific Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
11.2.7.1. Rest of Asia Pacific Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.7.2. Rest of Asia Pacific Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
11.2.7.3. Rest of Asia Pacific Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.7.4. Rest of Asia Pacific Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
 
Chapter 12. South America Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
12.1. South America Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
12.1.1. Market Route of Administration and projections, 2017 - 2028 (USD Million)
12.1.2. South America Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.1.3. South America Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
12.1.4. South America Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
12.1.5. South America Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
12.2. South America Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
12.2.1. Brazil Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
12.2.1.1. Brazil Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.1.2. Brazil Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
12.2.1.3. Brazil Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.1.4. Brazil Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.2. Argentina Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
12.2.2.1. Argentina Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.2.2. Argentina Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
12.2.2.3. Argentina Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.2.4. Argentina Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.3. Rest of South America Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
12.2.3.1. Rest of South America Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.3.2. Rest of South America Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
12.2.3.3. Rest of South America Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
12.2.3.4. Rest of South America Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
 
Chapter 13. Middle East & Africa Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
13.1. Middle East & Africa Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
13.1.1. Market Route of Administration and projections, 2017 - 2028 (USD Million)
13.1.2. Middle East & Africa Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
13.1.3. Middle East & Africa Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
13.1.4. Middle East & Africa Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
13.1.5. Middle East & Africa Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
13.2. Middle East & Africa Calcium Channel Blocker Market Overview, By Countries, 2017 - 2028 (USD Million)
13.2.1. GCC Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
13.2.1.1. GCC Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
13.2.1.2. GCC Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
13.2.1.3. GCC Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
13.2.1.4. GCC Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
13.2.2. South Africa Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
13.2.2.1. South Africa Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
13.2.2.2. South Africa Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
13.2.2.3. South Africa Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
13.2.2.4. South Africa Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
13.2.3. Rest of Middle East & Africa Calcium Channel Blocker Market Overview, 2017 - 2028 (USD Million)
13.2.3.1. Rest of Middle East & Africa Calcium Channel Blocker Market Overview, By Drug Class, 2017 - 2028 (USD Million)
13.2.3.2. Rest of Middle East & Africa Calcium Channel Blocker Market Overview, By Route of Administration, 2017 - 2028 (USD Million)
13.2.3.3. Rest of Middle East & Africa Calcium Channel Blocker Market Overview, By Indication, 2017 - 2028 (USD Million)
13.2.3.4. Rest of Middle East & Africa Calcium Channel Blocker Market Overview, By End User, 2017 - 2028 (USD Million)
 
Chapter 14. Competitive Landscape
14.1. Competitive Environment, 2021
14.2. Strategic Framework
14.2.1. Partnership/Collaborations/Agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New Product Development
 
Chapter 15. Key Vendor Analysis
15.1. Bausch Health
15.1.1. Business Overview
15.1.2. Product Benchmarking
15.1.3. Financial Data
15.1.4. Strategic Overview
15.1.5. Key Developments
15.1.6. SWOT Analysis
15.2. Mylan N.V.
15.2.1. Business Overview
15.2.2. Product Benchmarking
15.2.3. Financial Data
15.2.4. Strategic Overview
15.2.5. Key Developments
15.2.6. SWOT Analysis
15.3. Teva Pharmaceutical Industries Ltd
15.3.1. Business Overview
15.3.2. Product Benchmarking
15.3.3. Financial Data
15.3.4. Strategic Overview
15.3.5. Key Developments
15.3.6. SWOT Analysis
15.4. Lupin Pharmaceuticals, Inc.
15.4.1. Business Overview
15.4.2. Product Benchmarking
15.4.3. Financial Data
15.4.4. Strategic Overview
15.4.5. Key Developments
15.4.6. SWOT Analysis
15.5. Azurity Pharmaceuticals, Inc.
15.5.1. Business Overview
15.5.2. Product Benchmarking
15.5.3. Financial Data
15.5.4. Strategic Overview
15.5.5. Key Developments
15.5.6. SWOT Analysis
 
15.6. GSK Group
15.6.1. Business Overview
15.6.2. Product Benchmarking
15.6.3. Financial Data
15.6.4. Strategic Overview
15.6.5. Key Developments
15.6.6. SWOT Analysis
15.7. Sofgen Pharmaceuticals
15.7.1. Business Overview
15.7.2. Product Benchmarking
15.7.3. Financial Data
15.7.4. Strategic Overview
15.7.5. Key Developments
15.7.6. SWOT Analysis
15.8. Glenmark Pharmaceuticals Inc.
15.8.1. Business Overview
15.8.2. Product Benchmarking
15.8.3. Financial Data
15.8.4. Strategic Overview
15.8.5. Key Developments
15.8.6. SWOT Analysis
15.9. Amneal Pharmaceuticals
15.9.1. Business Overview
15.9.2. Product Benchmarking
15.9.3. Financial Data
15.9.4. Strategic Overview
15.9.5. Key Developments
15.9.6. SWOT Analysis
15.10. Sun Pharmaceutical Industries Ltd.
15.10.1. Business Overview
15.10.2. Product Benchmarking
15.10.3. Financial Data
15.10.4. Strategic Overview
15.10.5. Key Developments
15.10.6. SWOT Analysis
15.11. Novartis AG
15.11.1. Business Overview
15.11.2. Product Benchmarking
15.11.3. Financial Data
15.11.4. Strategic Overview
15.11.5. Key Developments
15.11.6. SWOT Analysis
15.12. Zydus Cadila
15.12.1. Business Overview
15.12.2. Product Benchmarking
15.12.3. Financial Data
15.12.4. Strategic Overview
15.12.5. Key Developments
15.12.6. SWOT Analysis
 
15.13. Pfizer Inc.
15.13.1. Business Overview
15.13.2. Product Benchmarking
15.13.3. Financial Data
15.13.4. Strategic Overview
15.13.5. Key Developments
15.13.6. SWOT Analysis
 
Chapter 16. Future Outlook of the Market